Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.

Experimental hematology - 1 Dec 2016

Ceglia Ilaria, Dueck Amylou C, Masiello Francesca, Martelli Fabrizio, He Wu, Federici Giulia, Petricoin Emanuel F, Zeuner Ann, Iancu-Rubin Camelia, Weinberg Rona, Hoffman Ronald, Mascarenhas John, Migliaccio Anna Rita

Abstract excerpt

To assess the role of abnormal transforming growth factor-beta (TGF-β) signaling in the pathogenesis of primary myelofibrosis (PMF), the effects of the TGF-β receptor-1 kinase inhibitor SB431542 on ex vivo expansion of hematopoietic cells in cultures from patients with JAK2V617+-polycythemia vera (PV) or PMF (JAK2V617F+, CALRpQ365f+, or unknown) and from normal sources (adult blood, AB, or cord blood, CB) were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Benzamides

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dioxoles

Share to Drug Evaluation, Preclinical

Share to Erythroblasts

Share to Fetal Blood

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Source

Open in PubMed Open full text

Identifiers

PMID: 27592389
DOI: 10.1016/j.exphem.2016.08.007
PMCID: PMC5778911

Genes

CALR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.PMID 27592389Read ↗

The role of TGFβ in hematopoiesis and myeloid disordersSemantic proximity Read ↗

Role of transforming growth factor-beta in hematologic malignancies.Semantic proximity Read ↗

TGF-β signaling and its role in the regulation of hematopoietic stem cellsSemantic proximity Read ↗

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.Semantic proximity Read ↗

TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.Semantic proximity Read ↗

Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.Semantic proximity Read ↗

Transforming growth factor-β signaling in normal and malignant hematopoiesisSemantic proximity Read ↗

Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.Semantic proximity Read ↗

Experimental therapy in myelofibrosis with myeloid metaplasia.Semantic proximity Read ↗

[Experimental model systems of primary myelofibrosis].Semantic proximity Read ↗

JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionalitySemantic proximity Read ↗

Understanding deregulated cellular and molecular dynamics in the haematopoietic stem cell niche to develop novel therapeutics for bone marrow fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.